Hormone Preparations Tied to Increased Bone Mineral Density in Postmenopausal Women

THURSDAY, May 11, 2023 (HealthDay News) -- Hormone preparations are associated with an increase in lumbar spine bone mineral density (BMD) in postmenopausal women, according to a study published online May 2 in Menopause.
Yiran Wang, M.D., and Chao Sun, M.D., from the First Affiliated Hospital of Xi'an Jiaotong University in China, evaluated the associations between hormone preparations with lumbar spine BMD, osteopenia, and osteoporosis in 6,031 postmenopausal women.
The researchers found a positive association between combined oral contraceptive pills, estrogen-only pills, estrogen/progestin combo pills, estrogen-only patches, or the use of more than two kinds of hormone preparations with lumbar spine BMD. Other hormone preparations also had a protective effect against osteopenia (all odds ratios less than 1.0), except for estrogen-only patches, but none of them were associated with osteoporosis prevalence. In the current and past users groups, BMD increased by 0.10 and 0.04 g/cm2, respectively, versus nonusers. The risk for osteopenia was reduced in both current and past user groups (odds ratios, 0.34 and 0.57, respectively).
"This large cross-sectional study showed that current and prior use of multiple types of hormone therapies, including combined hormone contraception used in premenopausal women and menopause hormone therapies, were linked with bone protection in postmenopausal women and that these effects persisted after discontinuation of treatment," Stephanie Faubion, M.D., medical director of the North American Menopause Society, said in a statement. "Additional study is needed to investigate the influence of time since stopping hormone therapy as well as the differential effects of various doses and formulations on bone health, including fracture risk."
Related Posts
Los casos de viruela del simio aumentan poco a poco en EE. UU., según los CDC
VIERNES, 10 de junio de 2022 (HealthDay News) -- Los casos de viruela del simio...
Atezolizumab Can Induce Response in Alveolar Soft Part Sarcoma
THURSDAY, Sept. 7, 2023 (HealthDay News) -- The immunotherapy agent atezolizumab...
In States Where Recreational Marijuana Legalized, Less Demand for Prescription Codeine
MONDAY, Jan. 23, 2023 (HealthDay News) -- New research suggests that there's one...
High-Risk Patients Awaiting Liver Transplant Benefit Most From Living Donors
WEDNESDAY, Oct. 11, 2023 (HealthDay News) -- High-risk cirrhosis patients...